Skip to content
Teethgrinder – Lifestyle
Author:
Jade Biosciences
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
April 22, 2026
←
Previous Page
1
2